It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Oral squamous cell carcinoma (OSCC) remains one of the most challenging clinical problems in the field due to its high rate of locoregional and distant metastases. However, studies that assess the association between aspirin use and survival in patients with OSCC are limited. Moreover, patients that recruited from those studies might have tumors that arose from different anatomic regions of the head and neck, including the oral cavity, oropharynx, etc. Since tumors within these distinct anatomic regions are unique in the context of epidemiology and tumor progression, we sought to evaluate the association of aspirin use with squamous cell carcinomas located within the oral cavity only. In this 10-year cohort study, we evaluated aspirin use and survival rates in relation to clinical characteristics as well as duration of aspirin use in patients with OSCC. Our findings suggest that OSCC patients with aspirin use for more than 180 days showed improved overall and disease-specific survival rates. Aspirin also improves survival in patients across various stages of OSCC. Cox regression models indicated that aspirin use was associated with a good prognosis. In conclusion, this evidence indicates that aspirin may be potentially used as an adjuvant therapy for OSCC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Department of Otolaryngology, Kaohsiung, Taiwan (GRID:grid.145695.a); Chang Gung University, Graduate Institute of Clinical Medical Sciences, College of Medicine, Taoyüan, Taiwan (GRID:grid.145695.a)
2 Chang Gung University, Graduate Institute of Clinical Medical Sciences, College of Medicine, Taoyüan, Taiwan (GRID:grid.145695.a); Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Department of Anesthesiology, Kaohsiung, Taiwan (GRID:grid.145695.a)
3 Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Department of Otolaryngology, Kaohsiung, Taiwan (GRID:grid.145695.a)
4 Chang Gung University, Graduate Institute of Clinical Medical Sciences, College of Medicine, Taoyüan, Taiwan (GRID:grid.145695.a); Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Department of Hematology-Oncology, Kaohsiung, Taiwan (GRID:grid.145695.a)
5 Chang Gung Memorial Hospital, Department of Traditional Chinese Medicine, Chiayi, Taiwan (GRID:grid.454212.4) (ISNI:0000 0004 1756 1410); Health Information and Epidemiology Laboratory of Chang Gung Memorial Hospital, Chiayi, Taiwan (GRID:grid.454212.4) (ISNI:0000 0004 1756 1410); Chang Gung University, School of Traditional Chinese Medicine, College of Medicine, Taoyüan, Taiwan (GRID:grid.145695.a)
6 Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Department of Hematology-Oncology, Kaohsiung, Taiwan (GRID:grid.145695.a)
7 Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Department of Radiation Oncology, Kaohsiung, Taiwan (GRID:grid.145695.a)
8 Chang Gung University, Graduate Institute of Clinical Medical Sciences, College of Medicine, Taoyüan, Taiwan (GRID:grid.145695.a); Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Division of Pulmonary and Critical Care Medicine, Kaohsiung, Taiwan (GRID:grid.145695.a)
9 National Chi Nan University, Department of Applied Chemistry, and Graduate Institute of Biomedicine and Biomedical Technology, Nantou, Taiwan (GRID:grid.412044.7) (ISNI:0000 0001 0511 9228); Chung Shan Medical University, Institute of Medicine, Taichung, Taiwan (GRID:grid.411641.7) (ISNI:0000 0004 0532 2041); Chung Shan Medical University Hospital, Department of Medical Research, Taichung City, Taiwan (GRID:grid.411645.3) (ISNI:0000 0004 0638 9256)